Daniel O’Connell joined Novo Holdings Venture Investments in 2022 as Partner based in the San Francisco office. Prior to joining Venture Investments, Daniel was Executive Director, Equity and Venture Capital/Corporate Development at BMS, where he was responsible for managing direct equity investments and LP positions in venture funds. Daniel has been an investor focused on private biotech opportunities at Arix Bioscience and OrbiMed. Daniel started his career at Arisaph Pharmaceuticals.
Daniel completed his undergraduate degrees at MIT, and his MD and PhD from Tufts University.